Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,052 results for ""INFLIXIMAB""

Your Filters

Publication : gut
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.

  • Authors : Jongsma MME; Paediatric Gastroenterology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.; Aardoom MA

Subjects: Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use

  • Source: Gut [Gut] 2022 Jan; Vol. 71 (1), pp. 34-42. Date of Electronic Publication: 2020 Dec 31.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.

  • Authors : Lu TX; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.; Indiana University Health Southern Indiana Physicians, Bloomington, IN, USA.

Subjects: Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*therapeutic use ; Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/*drug therapy ; Infliximab/Infliximab/Infliximab/*therapeutic use

  • Source: Gut [Gut] 2021 Nov; Vol. 70 (11), pp. 2076-2084. Date of Electronic Publication: 2020 Dec 17.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Subjects: COVID-19/COVID-19/COVID-19/*prevention & control ; COVID-19 Vaccines/COVID-19 Vaccines/COVID-19 Vaccines/*immunology ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*adverse effects

  • Source: Gut [Gut] 2021 Oct; Vol. 70 (10), pp. 1884-1893. Date of Electronic Publication: 2021 Apr 26.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Subjects: Antibodies, Viral/Antibodies, Viral/Antibodies, Viral/*immunology ; Antibody Formation/Antibody Formation/Antibody Formation/*immunology ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*therapeutic use

  • Source: Gut [Gut] 2021 May; Vol. 70 (5), pp. 865-875. Date of Electronic Publication: 2021 Mar 22.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.

Subjects: Health Care Costs*; Colectomy/Colectomy/Colectomy/*methods ; Crohn Disease/Crohn Disease/Crohn Disease/*therapy

  • Source: Gut [Gut] 2019 Oct; Vol. 68 (10), pp. 1774-1780. Date of Electronic Publication: 2019 Feb 01.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.

  • Authors : Hammoudi N; Department of Gastroenterology, AP-HP Hôpital Saint Louis, Paris, France.; Gardair C

Subjects: Colitis, Ulcerative/Colitis, Ulcerative/Colitis, Ulcerative/*drug therapy ; Infliximab/Infliximab/Infliximab/*adverse effects ; Mercaptopurine/Mercaptopurine/Mercaptopurine/*adverse effects

  • Source: Gut [Gut] 2019 Jun; Vol. 68 (6), pp. 976-995. Date of Electronic Publication: 2018 Oct 09.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.

Subjects: Adalimumab/Adalimumab/Adalimumab/*immunology ; Anti-Bacterial Agents/Anti-Bacterial Agents/Anti-Bacterial Agents/*therapeutic use ; Antibody Formation/Antibody Formation/Antibody Formation/*drug effects

  • Source: Gut [Gut] 2022 Feb; Vol. 71 (2), pp. 287-295. Date of Electronic Publication: 2021 Aug 03.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

Subjects: Antibodies/Antibodies/Antibodies/*blood ; Drug Monitoring/Drug Monitoring/Drug Monitoring/*methods ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*immunology

  • Source: Gut [Gut] 2018 May; Vol. 67 (5), pp. 818-826. Date of Electronic Publication: 2017 Apr 27.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.

  • Authors : D'Haens GR; Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands .; van Deventer S

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Colitis, Ulcerative/Colitis, Ulcerative/Colitis, Ulcerative/*drug therapy ; Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy

  • Source: Gut [Gut] 2021 Jul; Vol. 70 (7), pp. 1396-1405. Date of Electronic Publication: 2021 Jan 11.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.

  • Authors : Ben-Horin S; Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, Israel.; Yavzori M

Subjects: Antibodies/Antibodies/Antibodies/*immunology ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*immunology ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*immunology

  • Source: Gut [Gut] 2016 Jul; Vol. 65 (7), pp. 1132-8. Date of Electronic Publication: 2015 Apr 20.Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  1,052 results for ""INFLIXIMAB""